Eusa Pharma Company Profile

Aggregated data from the web about Eusa Pharma

Company Name	Eusa Pharma
Website	www.jazzpharma.com
Snippet	Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an Ireland-based biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. It was founded in 2003.[2] One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales.[1]
Type	Public
Brands	Xyrem, Erwinaze, Defitelio, FazaClo, FazaClo HD, Luvox CR, Prialt
Country	united kingdom
Founded	2005
Revenue	US$1.618 billion (2017)[1]
Website	www.jazzpharma.com
Industry	BiotechnologyPharmaceutical
Products	Pharmaceutical drugs
linkedin	linkedin.com/company/eusa-pharma
Traded as	NASDAQ: JAZZ
Key people	Bruce C. Cozadd, Chairman & CEO
Net income	US$487.8 million (2017)[1]
size_range	201 - 500
Area served	Worldwide
Predecessor	Jazz Pharmaceuticals, Inc.Azur Pharma plc
Headquarters	Dublin, Ireland
Total assets	US$5.123 billion (2017)[1]
Total equity	US$2.713 billion (2017)[1]
Operating income	US$528.8 million (2017)[1]
Number of employees	~1,210 (February 2018)[1]

Eusa Pharma is part of the Ireland company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.